Craig-Hallum raised the firm’s price target on Delcath Systems (DCTH) to $21 from $18 and keeps a Buy rating on the shares. Delcath delivered strong preliminary Q4 results that were ahead of expectations, as the holiday seasonality mentioned on the Q3 earnings call did not have the impact management expected, the analyst tells investors in a research note. The firm believes its estimates can still prove conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Reports Strong 2024 Financial Performance
- Delcath Systems sees FY24 revenue $37.2M, consensus $34.52M
- Delcath Systems sees Q4 revenue $15.1M, consensus $12.42M
- Delcath Systems Secures $16.3M from Warrant Exercise
- FDA finishes review of Delcath’s IND application of HEPZATO combo trial